心房颤动抗凝患者颅内出血的病例分析  

Case report of intracranial hemorrhage in a patient with atrial fibrillation undergoing the anticoagulant therapy

作　　者：宗宇桐 莫合塔伯尔·莫敏 王梓凝[1] 霍东波[2] 蒋捷[2] ZONG Yu-tongl;MOHETABOER·Mo-min;WANG Zi-ning;HUO Dong-bo;JIANG Jie(Department of Pharmacy,Peking University First Hospital,Beijing 100034,China;Department of Cardiology,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院药学部,北京100034 [2]北京大学第一医院心内科,北京100034

出　　处：《中国临床药理学杂志》2022年第15期1818-1820,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家“重大新药创制”专项基金资助项目(2018ZX09201014)。

摘　　要：本文通过介绍1例先后使用利伐沙班、艾多沙班抗凝,联合决奈达隆治疗心房颤动发生颅内出血的病例,分析颅内出血的可能原因,探论决奈达隆与Xa因子抑制药的相互作用,提示临床药师在心房颤动患者的治疗过程中需关注潜在的Xa因子抑制药的药物相互作用,对高危人群需严密监测各项检查指标,必要时进行抗Xa因子浓度监测,及时调整抗凝治疗方案;在发生药物浓度升高的情况下,不同口服抗凝药交替时需要酌情中断抗凝治疗,保障患者用药安全。In this paper, we analyzed the possible causes of intracranial hemmorrhage, discussed the interaction between dronedarone and factor Xa inhibitors through a case report of a patient with intracranial hemorrhage who used rivaroxaban and edoxaban successively, combined with dronedarone for the treatment of atrial fibrillation, suggesting that clinical pharmacists need to pay attention to potential drug-drug interactions of the factor Xa inhibitor in the treatment of patients with atrial fibrillation and that various test indicators should be closely monitored for high-risk groups, besides, if necessary, anti-Xa factor concentration monitoring should be carried out, and the anticoagulation treatment regimen should be adjusted promptly;in the case of increased drug concentration, when transitioning between different oral anticoagulants, anticoagulation needs to be interrupted as appropriate to ensure the safety of the patient medication.

关 键 词：利伐沙班 艾多沙班 决奈达隆 药物相互作用 

分 类 号：R972[医药卫生—药品]